Comparing the current results to its competitors, Safeguard Scientifics Inc reported Revenue decrease in the 4 quarter 2023 year on year by -81.33 %, despite the revenue increase by the most of its competitors of 8.95 %, recorded in the same quarter.
Safeguard Scientifics Inc, slower than the average decrease reported by the company's competitors of -27.84 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -27.84 %
Safeguard Scientifics Inc's Comment on Competition and Industry Peers
We face intense competition from other companies that acquire or provide capital
to healthcare and technology businesses. Competitors include venture capital and,
occasionally, private equity investors, as well as companies seeking to make strategic
acquisitions. Many providers of growth capital also offer strategic guidance,
networking access for recruiting and general advice. Nonetheless, we believe we
are an attractive capital provider to potential partner companies because our
strategy and capabilities offer:
responsive operational assistance, including strategy design and execution, business
development, corporate development, sales, marketing, finance, risk management,
talent recruitment and legal support;
the flexibility to structure transactions, with or without debt;
occasional liquidity opportunities for founders and existing investors;
a focus on maximizing risk-adjusted value growth, rather than absolute value growth
within a narrow or predetermined time frame;
interim C-level management support, as needed; and
opportunities to leverage Safeguard’s balance sheet for borrowing and stability.
